FDA sched­ules Covid-19 vac­cine ad­comm to dis­cuss po­ten­tial mod­i­fi­ca­tions and boost­ers

Af­ter the two years of suc­cess­ful up­take of Covid-19 vac­cines, the FDA is now look­ing to stream­line the reg­i­men of pri­ma­ry se­ries, boost­ers and bi­va­lents in the mix.

The FDA an­nounced Fri­day that it will be hold­ing an ad­comm next month, bring­ing to­geth­er its Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee (VRB­PAC) mem­bers in a bid to “con­sid­er whether and how the com­po­si­tion for pri­ma­ry dos­es of the cur­rent­ly avail­able COVID-19 vac­cines should be mod­i­fied and how and whether the com­po­si­tion and sched­ule for boost­er dos­es should be ad­just­ed mov­ing for­ward.” The meet­ing is cur­rent­ly slat­ed for Jan­u­ary 26.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER